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(Oct4) encodes a POU-domain tran-
scription factor (Scholer et al., 1990).
The gene is specifically expressed in
embryonic stem (ES) cells but can
also be detected in adult stem cells
such as bone marrow-derived mesen-
chymal stem cells (Pochampally et al.,
2004). Expression of Oct4 is down-
regulated during stem cell differentia-
tion. Oct4 plays a critical role in main-
taining pluripotency and self-renewal
of ES cells (Niwa et al., 2000; Pesce
and Scholer, 2001), but its utility as a
marker of pluripotency has been chal-
lenged recently by studies suggesting
that it is expressed in a variety of dif-
ferentiated cells, including peripheral
blood mononuclear cells (PBMCs)
(Tai et al., 2005; Zangrossi et al.,
2007). However, detection of Oct4
expression by RT-PCR could be prone
to artifacts generated by pseudogene
transcripts. We therefore have ana-
lyzed the sequences of human Oct4
and its pseudogenes and designed
PCR primers that can avoid false pos-
itive detection of Oct4 expression.
Pseudogenes are genomic DNA se-
quences similar to normal genes and
are regarded as defunct relatives of
functional genes (Vanin, 1985). There
are two types of pseudogenes: pro-
cessed and nonprocessed pseudo-
genes. Processed pseudogenes arise
by retrotransposition of mRNA and
are recognizable by the absence of
introns and 50 promoter sequences
(Pavlicek et al., 2002). This type of
pseudogene causes RT-PCR artifacts
if the DNase digestion before cDNA
synthesis is incomplete. As processed
pseudogenes look similar to the mRNA
transcript, DNA contamination of the
sample leads to amplification of a
fragment with the same size as the tar-
geted gene sequence. Nonprocessed364 Cell Stem Cell 1, October 2007 ª200pseudogenes result from duplications
within the genome and subsequently
acquire mutations, which lead to the
loss of functionality. This type of pseu-
dogene also has the potential to
generate artifacts in RT-PCR analysis.
Takeda et al. first described the exis-
tence of Oct4 pseudogenes (Takeda
et al., 1992), and transcription of
some Oct4 pseudogenes was de-
tected in cancer cell lines as well as
cancer tissues (Suo et al., 2005). In
mouse, a recently published paper
indicates that some of the putative
ES cell-specific pseudogenes may be
functionally important and that a novel
mouse Oct4 pseudogene can mediate
stem cell regulatory function (Lin et al.,
2007). These results show that some
of the known Oct4 pseudogenes are
transcribed in vivo and therefore could
lead to RT-PCR artifacts. Although this
information has been reported, it has
not been considered seriously in a
number of recent publications on adult
stem cells and tissue analysis referring
to Oct4.
For cancer tissue, Suo et al. (2005)
suggested analyzing both Oct4 and
all the pseudogenes. However, this
approach has limitations because the
total number of pseudogenes may
not yet be known, and use of pseudo-
gene-specific primers requires con-
siderable effort. We have therefore
designed a primer set that has the
potential to exclude all pseudogenes
known to date and detect only the
dominant splice variant of Oct4.
To approach this project, we began
with an initial alignment of Oct4 with
its alternative splice variants and its
pseudogenes. This alignment served
as a basis for an exact primer design.
Initially, we clarified the sequence and
organization of the functional human
Oct4 gene, to allow comparison to7 Elsevier Inc.the pseudogenes and alternatively
spliced transcripts. We searched the
NCBI human EST database and exam-
ined the UniGene cluster for Oct4
(NM002701). This yielded 13 mRNA
sequences and 129 EST sequences.
An additional BLASTn search of the
human genome using single exons of
Oct4 revealed several other highly
similar sequences. All these hits en-
coded complete or partial Oct4 se-
quences and could therefore repre-
sent either functional members of an
Oct4 gene family or pseudogenes. Our
primary focus was on the 13 mRNA
sequences retrieved by the UniGene
research and the sequences resulting
from BLASTn search. All sequences
including the original Oct4 sequence
were compared by using the alignment
program McAW. The result of the
alignment is depicted schematically
in Figure 1. In the upper alignment
(Figure 1A), the parental Oct4 mRNA
(NM002701) and the genomic locus
(NW92307) are shown in comparison
to alternatively spliced and other
Oct4 transcripts originating from
chromosome 6. The lower alignment
includes the two predicted mRNAs
from chromosome 1 XR019318 and
chromosome 12 XR16333 and their
corresponding DNA retropseudogene
sequences NG005794 and NG005793.
Also shown in Figure 1B are the RNA
sequences NR002304 and DQ486513
and the genomic sequence NT008046
deriving from chromosome 8. The
sequence DQ851566 is an Oct4-like
mRNA that was also included. This
alignment shows the high homology
of all pseudogene sequences com-
pared to the original Oct4 sequence.
The fact that so many homologous
sequences resemble the original Oct4
transcript makes an RT-PCR primer
design difficult, as numerous artifacts
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This figure contains the examined sequences of alternatively spliced variants and pseudogenes of
Oct4. It also depicts the genomic organization of the genomic Oct4 locus. (A) Alternatively spliced
variants of Oct4 on chromosome 6. (B) Processed and nonprocessed pseudogenes of Oct4 on
other chromosomes. For a detailed alignment, see Figure S2.could arise during amplification. We
therefore used our analysis to design
primers that are able to exclude ampli-
fication of all unwanted transcripts. We
designed two different forward primers
(see Table S1). One (Oct4_F_P) carries
a polymorphism at the 30 end, which
is unique in Oct4 and can distinguish
between the parental transcript and
the pseudogenes on chromosomes 1
and 8. The other forward primer
(Oct4_F) is located in a region that is
not homologous to pseudogene se-
quences. The reverse primer (Oct4_R)
is intron spanning and is designed to
avoid amplification of DNA. Table S2B
shows alignment of two of these
primers, Oct4_F and Oct4_R, with
alternatively spliced Oct4 sequences
and pseudogenes.
We also examined some of the pre-
viously published primers in light of our
alignment. Table S2A shows that one
set of published primers (Tondreauet al., 2005) located in exons 3 and 5
has significant sequence overlap with
alternatively spliced Oct4 sequences
and pseudogenes. In fact, on chromo-
some 6 only sequence S81255 has any
mismatch with the forward primer of
this set. All other sequences have a
full match to either the forward or the
reverse primer. Similarly for the pseu-
dogenes, in three of eight cases the
reverse primer has only a single mis-
match. We also analyzed several other
published primers used for Oct4 RT-
PCR and found that the majority of
them lie in exons 2–5 where the high-
est homology to alternatively spliced
variants and pseudogenes occurs.
Figure 2 shows the validation of the
new proposed primer sets by RT-PCR
analysis. Figures 2A and 2B show the
results of a preliminary gradient PCR
to determine adequate annealing con-
ditions of the used primer. The malig-
nant pluripotent embryonal carcinomaCell Stem Cell 1cell line NTERA-2 was used as tem-
plate, and both cDNA and DNA were
tested. As expected, we obtained
Oct4 products using cDNA but no
products from DNA. These PCR re-
sults confirm that our proposed primer
sets can discriminate between the
parental Oct4 product and retro-
pseudogenes. The products were then
further investigated by sequence
analysis. The sequences (see Table
S3 and Figure S1) confirmed again
that only the normal Oct4 transcript
(NM002701) was amplified by RT-
PCR. Our proposed primer sets were
further tested on mononuclear cells
(MNCs) from cord blood and PBMCs.
Zangrossi et al. (2007) showed that
RT-PCR amplification of total RNA
from MNCs and PBMCs yielded prod-
ucts contributed by genomic DNA
contamination and mRNA transcripts
encoding Oct4. We obtained the
same results using their primers. How-
ever, we did not obtain products from
MNCs and PBMCs using our pro-
posed primer sets. This comparison
therefore provides an illustration of
how correct primer design can avoid
amplification of unwanted or irrelevant
sequences.
At this point, expression of Oct4 has
been reported in adult stem cells as
well as in a variety of differentiated
cells (Pochampally et al., 2004; Tai
et al., 2005; Tondreau et al., 2005;
Zangrossi et al., 2007). However, our
analysis shows that it is possible that
the detected Oct4 signal came from
alternatively spliced or Oct4 pseudo-
gene transcripts rather than from
bona fide Oct4 expression. As shown
here, precise design of Oct4-specific
primers is a prerequisite for accurate
RT-PCR analysis. As many pluripo-
tency-associated genes, such as
NANOG, also have several pseudo-
genes (Booth and Holland, 2004; Rob-
ertson et al., 2006), a similar analysis
would seem to be necessary to avoid
false positive results derived from
other pseudogene products. In addi-
tion, the RT-PCR analysis should be
verified by western blot analysis. In
fact, the available antibodies could
prove very valuable in studying the
expression and function of Oct4 in
view of the putatively expressed pseu-
dogenes and splicing variants of Oct4., October 2007 ª2007 Elsevier Inc. 365
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(A) Gradient PCR on NTERA-2 cell cDNA (upper) and DNA (lower) with Oct4_F forward primer and
Oct_R reverse primer. These primers amplify a fragment that could be ascribed exclusively to
transcript variant 1 (NM002701) and excludes transcript variant 2 (NM203289) as well as all known
pseudogenes.
(B) Gradient PCR NTERA-2 cell cDNA (upper) and DNA (lower) with Oct4_F_P forward primer that
contains a polymorphism to discriminate between parental Oct4 and pseudogenes on chromo-
somes 1 and 8.
(C) PCR at 63C annealing temperature with different Oct4 primer pairs. The primers in the bottom
row were taken from Zangrossi et al. (2007).
For primer sequences, see Table S1.We hope that our findings will help
other stem cell researchers to devise
appropriate tools for RT-PCR analysis
and provide an illustration of how mis-
leading artifacts can be avoided by us-
ing a detailed alignment as a starting
point for designing appropriate primers.
Supplemental Data
Supplemental Data include three tables,
two figures, and Supplemental Experimental
Procedures and can be found with this article366 Cell Stem Cell 1, October 2007 ª200online at http://www.cellstemcell.com/cgi/
content/full/1/4/364/DC1/.
ACKNOWLEDGMENTS
We thank Dr. Colin R. MacKenzie (Institute of
Medical Microbiology and Hospital Hygiene,
Heinrich-Heine-University, Du¨sseldorf) for
critically reading this manuscript. The NTERA-2
cell line used in the experiment here was
kindly provided by Dr. Axel Methner
(Department of Neurology, Heinrich-Heine-
University, Du¨sseldorf).7 Elsevier Inc.REFERENCES
Booth, H.A., and Holland, P.W. (2004). Geno-
mics 84, 229–238.
Lin, H., Shabbir, A., Molnar, M., and Lee, T.
(2007). Biochem. Biophys. Res. Commun.
355, 111–116.
Niwa, H., Miyazaki, J., and Smith, A.G. (2000).
Nat. Genet. 24, 372–376.
Pavlicek, A., Paces, J., Zika, R., and Hejnar, J.
(2002). Gene 300, 189–194.
Pesce, M., and Scholer, H.R. (2001). Stem
Cells 19, 271–278.
Pochampally, R.R., Smith, J.R., Ylostalo, J.,
and Prockop, D.J. (2004). Blood 103, 1647–
1652.
Robertson, M., Stenhouse, F., Colby, D.,
Marland, J.R., Nichols, J., Tweedie, S., and
Chambers, I. (2006). Mamm. Genome 17,
732–743.
Scholer, H.R., Ruppert, S., Suzuki, N., Chowd-
hury, K., and Gruss, P. (1990). Nature 344,
435–439.
Suo, G., Han, J., Wang, X., Zhang, J., Zhao, Y.,
and Dai, J. (2005). Biochem. Biophys. Res.
Commun. 337, 1047–1051.
Tai, M.H., Chang, C.C., Kiupel, M., Webster,
J.D., Olson, L.K., and Trosko, J.E. (2005). Car-
cinogenesis 26, 495–502.
Takeda, J., Seino, S., and Bell, G.I. (1992).
Nucleic Acids Res. 20, 4613–4620.
Tondreau, T., Meuleman, N., Delforge, A.,
Dejeneffe, M., Leroy, R., Massy, M., Mortier,
C., Bron, D., and Lagneaux, L. (2005). Stem
Cells 23, 1105–1112.
Vanin, E.F. (1985). Annu. Rev. Genet. 19, 253–
272.
Zangrossi, S., Marabese, M., Broggini, M.,
Giordano, R., D’Erasmo, M., Montelatici, E.,
Intini, D., Neri, A., Pesce, M., Rebulla, P.,
and Lazzari, L. (2007). Stem Cells 25, 1675–
1680.
Accession Numbers
The EMBL accession numbers for sequences
termed 1–12 reported in this paper are
AM851115–AM851126.
